Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 6Enrolling by invitation 3Unknown 2Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Dermatologic 2Classical hematology 2Breast 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Brain Neoplasms 1050Glioblastoma 920Glioma 601Central Nervous System Neoplasms 436Astrocytoma 396Gliosarcoma 339Neuroblastoma 325Oligodendroglioma 255Neoplasms 181Medulloblastoma 165Breast Neoplasms 154Sarcoma 114Recurrence 108Ependymoma 105Neoplasm Metastasis 95Meningioma 91Melanoma 88Lymphoma 87Carcinoma, Non-Small-Cell Lung 87Lung Neoplasms 82Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Neurofibromatosis 1 78Wilms Tumor 75Osteosarcoma 69Head and Neck Neoplasms 69Ovarian Neoplasms 68Testicular Neoplasms 67Lymphoma, Non-Hodgkin 67Burkitt Lymphoma 66Familial ependymoma 63

Interventions

fluorodopa F 18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Parkinson Disease × CNS × Clear all
NCT03042416 2022-01-10

18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety

University of Alberta

Phase 3 Completed
400 enrolled
CNSEndocrineNET

Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡